Blunted optimismThe government last week announced a pact with CureVac NV to tackle variants, pairing artificial intelligence to predict future mutations with messenger RNA technology that can rapidly generate new vaccines.
After a once-promising partnership with Sichuan Clover Biopharmaceuticals Inc. ended and separate trials with Sanofi ran into delays, London-based GlaxoSmithKline Plc is also working with CureVac on mutant-quelling vaccines.Meanwhile, countries across the European Union, which has lagged the U.S.